Tuesday, December 15, 2020
Peer-reviewed data for Pfizer Inc.’s BNT162b2 mRNA COVID-19 vaccine candidate was published by the New England Journal of Medicine (NEJM), confirming its safety and efficacy. The study’s authors concluded that a two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in individuals 16 years of age or older, with safety over a median of two months similar to that of other viral vaccines.
You can read the full article here: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=featured_home
Thursday, December 17, 2020
Thursday, September 3, 2020
Thursday, August 6, 2020
Tuesday, July 7, 2020
Sunday, June 28, 2020
Monday, June 22, 2020
Thursday, June 4, 2020
Sunday, May 17, 2020
Monday, April 13, 2020
Sunday, April 5, 2020
Wednesday, March 18, 2020
Tuesday, March 17, 2020
Thursday, March 12, 2020
Thursday, March 5, 2020
Wednesday, March 4, 2020